Navigation Links
Kite Pharma Completes $35 Million Series A Preferred Stock Financing
Date:5/15/2013

LOS ANGELES, May 15, 2013 /PRNewswire/ -- Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has closed a $20 million private placement of shares of its Series A Preferred Stock. In addition to the $20 million in new funds, Kite converted $15 million in outstanding promissory notes into shares of Series A Preferred Stock. Joined by a new investor, Alta Partners, all existing major investors participated in the financing, including Kite's Founder and Executive Chairman, Arie Belldegrun , M.D., David Bonderman , Pontifax Ltd., Commercial Street Capital, and Michael Milken.

(Logo: http://photos.prnewswire.com/prnh/20130513/MM13332LOGO)

Kite is engaged in the development of novel cancer immunotherapeutic products with a focus on engineered autologous T cell therapy (eACT), designed to restore a patient's immune system by recognizing and eradicating tumors. In partnership with the National Cancer Institute (NCI) Surgery Branch under a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates directed at a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are aimed at providing significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments.

"We are extremely pleased with the significant level of interest in Kite and its programs by our existing investors and by Alta Partners, a premier life sciences investment firm," said Aya Jakobovits , Ph.D., President and Chief Executive Officer of Kite Pharma. "The new resources will allow us to advance clinical and manufacturing activities of eACT products directed to hematological and solid tumor indications."

In connection with the financing, Farah Champsi , Managing Director of Alta Partners, and Ran Nussbaum, Managing Partner of Pontifax, have joined Kite's Board of Directors. "We are pleased to welcome Farah and Ran, who will be adding their expertise to a very active and engaged Board," said Arie Belldegrun. "Their experience within the life sciences industry will be valuable to us as Kite enters its next stage of development and growth."

"Kite's eACT technology has the potential to provide cancer patients with a treatment that offers a significant and durable impact on their disease," said Farah Champsi . "The product pipeline directed to different tumor types, combined with the company's experienced management team, positions Kite to become a leader in this breakthrough therapeutic modality. I am excited to work again with Drs. Belldegrun and Jakobovits to realize the potential of this product platform."

About the eACT Platform
Clinical evidence has demonstrated that a patients' peripheral blood T cells, which have been engineered with T cell receptor (TCRs) and Chimeric Antigen Receptors (CARs) that recognize tumor specific molecules, can traffic directly to the tumor, become activated upon engagement with the tumor antigen, and selectively eradicate tumors. Clinical studies performed at the National Cancer Institute using these types of engineered peripheral blood T cells have been associated with significant and durable objective clinical responses in cancer patients with advanced metastatic disease, including those with refractory melanoma, sarcoma, lymphoma and leukemia. These encouraging results highlight eACT as an emerging therapeutic modality that could provide new personalized targeted therapy options for cancer patients spanning the spectrum of disease from its early stages to the salvage setting.

About Kite Pharma
Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapeutic products, with focus on engineered autologous T cell therapeutics targeted to different tumor types. In addition, the company is advancing a novel therapeutic cancer vaccine aimed to trigger potent and specific immunity against multiple epithelial cancers, which has the potential to complement its eACT programs.  

Kite is based in Los Angeles, CA. For more information, visit the company's website at www.kitepharma.com.

Contact:
Aya Jakobovits , Ph.D.
President and Chief Executive Officer
Kite Pharma, Inc.
(310) 824-9999 x 201
ajakobovits@kitepharma.com

For Media:
Joan Kureczka
Kureczka-Martin Associates
Ph: (415) 821-2413
M: (415) 690-0210
Joan@kureczka-martin.com


'/>"/>
SOURCE Kite Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. To Present At The UBS Global Health Care Conference
2. Savient Pharmaceuticals Reports First Quarter 2013 Financial Results
3. The Law Offices of Marc S. Henzel Announces Class Action Lawsuit Against Aveo Pharmaceuticals, Inc. and Certain Officers -- (Nasdaq: AVEO) was filed on behalf of stockholders
4. PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
6. PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
7. Halo Pharma And Altus Formulation Announce New Formal Collaboration
8. Astellas Joins the National Pharmaceutical Council
9. Callidus Biopharma Announces $4.6 million in Series A Financing to Pursue Orphan Disease Therapies
10. Research Solutions Launches New Software-as-a-Service Compliance Solution for Pharmaceutical Companies
11. Sunshine Act Compliance Simplified for Pharmaceutical Drug Manufacturers with New Medical ePrint Solution from Reprints Desk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... College District , the only authorized OSHA Training Institute Education Center headquartered in ... by protecting their workers from extreme heat at their worksites. Employers with ...
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... professionals, announced today its affiliation with Tennessee Counseling Association. This new ... network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):